Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
This empowers countries with superior negotiating powers a leverage, [ii] typically developed nations in the context of developed-developing country partnerships. Here, developing a new medicine requires substantial investment which comes with a high degree of uncertainty. [iv] 6, 2024). [ii] Kaplan, W.A.,
Let's personalize your content